Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical reviewRUBBERT-ROTH, Andrea; FINCKH, Axel.Arthritis research & therapy (Print). 2009, Vol 11, pp 1-12, issn 1478-6354, 12 p., SUP1Article

Assessing the safety of biologic agents in patients with rheumatoid arthritisRUBBERT-ROTH, Andrea.Rheumatology (Oxford. Print). 2012, Vol 51, issn 1462-0324, v38-v47, SUP5Article

Successful use of rituximab in a patient with Churg-Strauss syndrome and refractory central nervous system involvementSAECH, Jasemine; OWCZARZYK, Kasia; RÖSGEN, Sylvia et al.Annals of the rheumatic diseases. 2010, Vol 69, Num 6, pp 1254-1255, issn 0003-4967, 2 p.Article

Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugsPAVELKA, Karel; KAVANAUGH, Arthur F; RUBBERT-ROTH, Andrea et al.Rheumatology (Oxford. Print). 2012, Vol 51, issn 1462-0324, v12-v21, SUP5Article

Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)RUBBERT-ROTH, Andrea; TAK, Paul P; ZERBINI, Cristiano et al.Rheumatology (Oxford. Print). 2010, Vol 49, Num 9, pp 1683-1693, issn 1462-0324, 11 p.Article

Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of ExposureGENOVESE, Mark C; RUBBERT-ROTH, Andrea; SMOLEN, Josef S et al.Journal of rheumatology. 2013, Vol 40, Num 6, pp 768-780, issn 0315-162X, 13 p.Article

Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGETAK, Paul P; RIGBY, William; RUBBERT-ROTH, Andrea et al.Annals of the rheumatic diseases. 2012, Vol 71, Num 3, pp 351-357, issn 0003-4967, 7 p.Article

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study) : a double-blind, placebo-controlled, randomised trial. CommentaryBONGARTZ, Tim; SMOLEN, Josef S; BEAULIEU, Andre et al.Lancet (British edition). 2008, Vol 371, Num 9617, issn 0140-6736, 961-963, 987-997 [14 p.]Article

Efficacy and Safety of Rituximab Treatment in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitides: Results from a German Registry (GRAID)ROLL, Petra; OSTERMEIER, Eva; SPECKER, Christof et al.Journal of rheumatology. 2012, Vol 39, Num 11, pp 2153-2156, issn 0315-162X, 4 p.Article

Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysisEMERY, Paul; MEASE, Philip J; RUBBERT-ROTH, Andrea et al.Rheumatology (Oxford. Print). 2011, Vol 50, Num 12, pp 2223-2232, issn 1462-0324, 10 p.Article